Skin Solution Archives - Forest Hills Lab

Luis Angel Rojas-Graterol MS

About

8+ Years of experience working in the pharmaceutical, medical device, CRO, and Health Services industry.
Proficient skills in Protocol and SAP development, statistical programming, CDISC, eCRF and data review, and many other aspects associated with clinical trials
Solid experience in phase I to III studies using fixed and adaptive design features [in several therapeutic areas including Rare Diseases, Autoimmune, Cardiovascular, Endocrine, Neuromuscular, COVID-19, Biomarkers (Oncology), Medical Devices, and Sleep Disorders]
Luis received his MS in Applied Statistics from the University of Delaware and BS in Psychology (Pre-Medicine Track) from Loyola University Chicago

Dr. Khalid Iqbal

About

Professor of Neuroscience and Chairman, Department of Neurochemistry, at the New York State Institute for Basic Research in Developmental Disabilities
Conducted pioneering studies on neuronal protein pathology and discoveries of tau protein and its abnormal hyperphosphorylation in Alzheimer disease
Awards for Alzheimer’s disease research include the Potamkin Prize for Alzheimer Disease Research from the American Academy of Neurology and the Zenith Award from the Alzheimer’s Association, U.S.A
Dr. Iqbal received his Ph.D. in Biochemistry from the University of Edinburgh

KECO KAM

About

Comprehensive business management with demonstrated track record in international corporations
Experience in Consumer Goods, Health and Wellness, Aesthetics markets
MSc in Marketing, The Chinese University of Hong Kong
Professional Certificate in Digital and Social Media Marketing at Hong Kong Polytechnic University, Institute of Entrepreneurship

ELLA FONG

About

Commercial leader with proven successful records of scaling up and driving strong business performance in MNCs
BU and Market Head of Hong Kong & Macau (Aesthetics & Dermatology Prescription Medicines) at Galderma HK
Director & Head of Sales of HK, Macau and CBEC China at Abbott
Head of Shopper Marketing | Associate Sales Director – Hong Kong & Macau | Head of Taiwan Business at FrieslandCampina (The world’s largest dairy cooperatives)
Key Account Sales Manager at market beverages leader Swire Coca-Cola

Peter Lee

About

Over 25 years in sales engineer, medical devices for beauty equipment
Sales and planning Dermal Filler production plant
Managing Beauty Clinic (Dermatology, Plastic Surgery, Medical Aesthetics, Oriental Clinic)
Managing IT Business
Planning New Business
Technical Training Course, Medical Lasers, Israel, US, Germany
Training Course, Aesthetics Devices, Korea
Training Course, Cosmetics, Korea

Jason Park

About

Graduated from Sun Yat-sen University, China
Account service in manufacturing and distribution management of LG Household & Health Care
Good knowledge in the market operations of cosmetics in China, especially for export and import documentation and approval of certificates
Years of experience in consulting service of Chinese beauty market, i.e., the plastic surgery, dental clinic and medical aesthetics

Ik Hwan Cho

About

Over 30 years of experience in pharmaceutical and cosmeceutical R&D, production and quality administration, RA and relations management with government authorities
2 years at NIH (National Institute of Health) in pharmaceutical and clinical R&D
Member of KFDA’s Biopharma Industry Cooperation Committee and operating chair of Biopharma Overseas Trade Subcommittee
M.S. in biology, B.S. in food engineering

B. Kyle Park

About

Founder and CEO of Bright Stone Partners, manager of private equity fund based in South Korea investing in offshore bio-tech companies and onshore alternative assets
Over 15 years of experience in advising private fund formation and executing cross-border transactions including M&A and asset sales and acquisitions
Senior foreign attorney/Partner at Kim & Chang
LL.M. from Georgetown University Law Center, LL.M. from New York University School of Law, J.D. from American University
Admitted to the State of New York and District of Columbia Bars

Andrew O

About

Senior Portfolio Manager and Managing Director at Manulife Investment Management. Portfolio Manager for the Asia Pacific Ex-Japan Small Cap Fund and Korea Specialist Portfolio Manager for larger regional mandates. Full investment discretion and responsible for portfolio construction; single stock fundamental analysis, position sizing, monitoring and liquidation; sector and country allocation management; specialist team management; P&L, risk and volatility management. Principal role marketing to and communicating with institutional investors.
Managing Director at Horizon Asset International; Portfolio Manager running an Asia Ex-Japan Long-Short fundamental book.
Executive Director and Head of Research at FrontPoint Partners (Morgan Stanley Investment Management subsidiary) for the Asia Ex-Japan Long-Short fundamental package.
Executive Director at Goldman Sachs in the Equities Division focused on the Korean equities franchise.
Assistant Investment Officer in the Asia Financial Markets group at the International Finance Corporation, the World Bank’s private investment arm.
Graduated from the University of Pennsylvania with BA degrees in American Civilization and English and undertook Master’s level studies at Yonsei University’s Graduate School of International Studies.

Valerie Yeung

About

Member of the Hong Kong Institute of Certified Public Accountant
BSc, Accounting and Finance, University of Bristol
Background in auditing and corporate finance
Years of experience in risk advisory specializing in pre-IPO internal control and risk management
Broad international industry exposure in e-commerce, financial services, manufacturing, retail, property development, etc
Strong exposure in listing for Chinese entities

Puraxel
Aesthetic E_r: Yag Laser

– Combined Puraxel AESTHETIC Er: YAG LASER
with Nuvogen Orchestra provides skin rejuvenation treatment, result in younger looking and better skin. Effects go to the epidermis layer in a non-invasive way, no pain. What the Magic!

XSPURT ™
HA FILLER

– Xspurt HA Filler give volumization contouring while Secret Plus+ High Indensity Focused Ultrasound System gives Face V-Lifting(Deep into your skin). Amazing Effect!

Dr. Mitchel S. Berger, M.D., F.A.C.S., F.A.A.N.S

About

Dr. Berger serves as a Director of Brain Tumor Research Centre in University of California.
Dr. Berger completed his 23-year tenure as Chair of Neurological Surgery at UCSF.
Dr. Berger was elected to the American Association of Neurological Surgeons’ board of directors and appointed to the American Board of Neurological Surgery.
Invited to one of the 20-member Blue Ribbon Committee under Biden administration as an exceptional and prominent medical professional
Dr. Berger received his bachelor’s degree from Harvard University and his medical degree from the University of Miami Miller School of Medicine.

Dr. Han-Jun Kim, M.D., Ph.D.

About

Dr. Kim is a clinical professor at the Department of Neurology at Seoul National University Hospital for more than 20 years with the main focus on neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, etc.
Dr. Kim has graduated from Seoul National University for his MD, MS and PhD and completed his internship and residency at SNUH.
Dr. Kim currently serves as a professional consultant to FHL for the clinical trial design and patient recruitment considerations.

David Han

About

Over 20 years of experience in debt and equity capital market products, primary distribution, private equities, investment execution, regulatory compliance, and corporate and project management
Director, Sun Healthcare International
Director, Vision Asset Management, fund organization execution, internal control and regulatory compliance
Director, Incap Investment, private placements of debt and equities, project finance
CFO at HNT Electronics, financial planning and budgeting, credit management, investor relations and capital placements
Director at NuVista Capital, private placements of debt and equities
Director at Kamway Investment, origination and distribution of notes and debt securities to primary market investors
BA in Finance at University of Southern California

Anthony Lam

About

Former Chief Investment Officer of Transpac Capital Limited where his responsibilities include defining investment strategy and market positioning, leading recruitment efforts to build investment team, and leading fund raising efforts on USD and RMB PE funds. Responsible for identifying, structuring and closing transactions.
Former Managing Director and Head of China for Asia Climate Partners (“ACP”) managing a US$450 million fund. ACP targets investments in renewable energy, resource efficiency and environmental industries in emerging Asia with a strong focus on China, India and SE Asia.
Former Managing Director and Co-Head of Asia Pacific for The Rohatyn Group. Here he served on global investment and management committee with responsibility for the investment management process including advising, research and execution in an asset management capacity. Managed an outstanding portfolio of 7 investees with total investment amount of over $600 million in China, Singapore, South Korea as well as Thailand.
Former Partner at Citigroup Venture Capital International. Here he was responsible for sourcing, advising, executing and monitoring private equity investments in Asia Pacific.

Alexandre Choumert

About

Multilingual and problem solver with significant experience in the luxury retail industry in multicultural environments (USA, Latin America, Europe, Asia). Strong foundation in Finance, Strategic Planning & Analysis.
Business Development Manager for an airline and fundraising / enhancing customer base for Fintech, Insurtech, AI and Blockchain startup companies.
Change leader with broad business acumen, diversified industry experience (retail, airline, pharma & energy sectors).
Master of Business Administration from Northeastern University (Boston).

Sally Tam

About

Former e-commerce manager of pharmaceuticals and healthfood companies, familiar with the ecommerce growth across all marketplaces and explore opportunities to expand new partnership.
Experience in developing different online channel, including but not limited to, Wechat, Tmall/Taobao, JD, Xiaohongshu, Douyin(TikTok), Weibo, Facebook, Instagram
Former officer of various pharmaceuticals, medical & beauty companies, strong exposure in various kinds of trade show and exhibitions e.g. Hong Kong International Medical and Healthcare Fair, Cosmoprof, Sisters BeautyPro Trade Fair and HOFEX
Member of Hong Kong Information Technology Joint Council
B Sc.in Business Information Technology at the University of Central England in Birmingham

Daniel Huang

About

Former strategy consulting professional at Health Advances, a boutique healthcare-focused consulting firm. Advised management teams and investors on topics including growth strategy, due diligence, and portfolio forecasting. Member of the APAC office’s founding team. Areas of focus include novel drug therapies and digital health solutions
Former experience in medical device start-ups in the neurosurgical space. Co-inventor on a patent for a novel drug delivery technology and secured non-dilutive funding to support iterative product development. Diverse roles included product design, engineering, business development, and fundraising
Formerly conducted biophysics research at Johns Hopkins Hospital, using single-molecule methods to study the dynamics of protein-nucleic acid complexes
B.S. in Biomedical Engineering from Johns Hopkins University with distinction

Luis A Rojas, PhD

About

Highly experienced Research Scientist Statistician with 30+ years in the pharmaceutical, medical device, CRO, and academia industry.
Subject-Matter Expert (SME) in Study Design / Adaptive Design for Phase I through Phase IV studies.
More than 20 years of leadership and project management experience, including managing global staff of 140+ Biostatisticians and Statistical Programmers.
Former Head of Study Designs / Adaptive Design unit within Advisory Service Analytics / Center for Statistics in Drug Development in IQVIA, while acting as lead Senior Research Scientist Statistician for the GI, Rare Diseases, Ophthalmology, CNS, Lupus, RA Center of Excellence.
Dr. Rojas received his PhD in Research Statistics from the Rafael Belloso Chacin, Venezuel

Mary Shatzoff M.S.

About

25 years in Regulatory Affairs of pharmaceutical industry in clinical drug development
Experience working at Sanofi Aventis, Pfizer and as an independent consultant
Contributed to over 100 drug and biologic product applications and participated in development and marketing approval of products with therapeutic areas: Anti-Infective, Gastroenterology, Dermatology, Urology, Neurology
Experience with regulatory bodies such as FDA (CDER and CBER); OOPD (orphan). EU; EMA, Canada (HC) and Australia; TGA

Colleen Johnson, M.S., D.A.B.T.

About

Toxicology consultant assisting small- to mid-sized pharmaceutical companies with all aspects of nonclinical development which includes monitoring studies, interacting with toxicology laboratories, representing sponsors at regulatory agencies, and preparing regulatory submissions.
Member of the International Society of Regulatory Toxicology and Pharmacology, the Roundtable of Toxicology Consultants, and the American College of Toxicology.
Associate Member of Society of Toxicology.
Board certified with the American Board of Toxicology.
BSc.Phm. at the University of California Santa Barbara, M.S.in Pharmacology and Toxicology at the University of Arizona.

Hahn-Jun Lee, Ph.D.

About

Founder/CEO of Epygenix Therapeutics and Polaryx Therapeutics
Over 20 years of involvement in R&D, licensing, deal-making, business development, and company creation
Former consultant for top healthcare venture capital firms, global pharma and biotech companies including Doman Associates, Solidus Investment, Shire Human Genetic Therapies, P&G Pharmaceuticals, Melior discovery, CDI Diagnostics, RegeneRx Biopharmaceuticals
Former consultant for Korean biotech companies including Binex, Alteogen, CMG Pharma, and research institutes including Korea Research Institute of Chemical Technology (KRICT)
Former Assistant Professor of Biotechnology in the Department of Orthopedic Surgery, Columbia University
Formerly, Staff Scientist at the RIKEN Brain Science Institute in Japan
B.Sc. in Life Sciences in Sogang University, and M.Sc. and Ph.D. in applied biotechnology in University of Tokyo, Japan.

Joo Young Moon

About

Over 30 years management, operation, planning and development experience in healthcare
Founding member and Chief of Operation of Seoul National University Bundang Hospital (SNUBH) Planning Division and Gangnam Healthcare Center
Current board member of Korean Society of Hospital Management and Korea College of Hospital Managers
Director in charge of a successful 5-year contract for consignment operation of UAE Sheikh Khalifa Specialty Hospital (SKSH) by Seoul National University Hospital (SNUH)
Chairperson of Public-Private Joint Committee for the globalization of Medical Korea
Vice President of Hospital Administration at SNUH
Director of Global Planning and Development, SNUH, General Manager for SNUH Abu Dhabi Foreign Branch, UAE, and CFO of SNUH USA. Inc.
Member, Presidential Delegation for Economic Cooperation with Teheran University Hospital

Alex Yang

About

Currently, CEO of Mstone and Curyx Partners, engaged in establishing and managing a portfolio of therapeutic drug development companies
Over 20 years of experience in advising and executing fund formation, cross-border transactions and a diverse pool of investment opportunities in multiple sectors
Investment and risk committee members for regional and country-focused private equity funds and director roles for both listed and private companies
Managing Partner at Kim & Chang Hong Kong office
Partner at Ernst & Young Hong Kong office to lead Asian financial services practice
Private equity investment professional and In-house counsel at Morgan Stanley
International tax advisor at Coopers & Lybrand and Ernst & Young New York offices
JD and LLM at New York University School of Law; BS Economics, Binghamton University
Bar with the State of New York and registered foreign attorney with Hong Kong Law Society

Dr. Kalipada Pahan, Ph.D.

About

Professor of Neurological Sciences, Biochemistry and Pharmacology, and the Floyd A. Davis, MD.D., Endowed Chair at Rush University Medical Center.
Research Scientist at the Jesse Brown VA Medical Center.
Award-winner of The Zenith Fellows Award 2017, the highest honor award by Alzheimer’s Association.
Senior editor of Journal of Neuroimmune Pharmacology.

Dr. Shrijay Vijayan Ph.D.

Experince: 10 Years

About

Jay Vijayan is Director of Innovation and Technology Commercialization at the Hospital for Special Surgery (HSS), where he is responsible for the commercialization of life science technologies.
Dr. Vijayan began his career in technology transfer at the University of Illinois. He was then recruited to Rutgers University as Assistant Director, Licensing. Prior to joining HSS, Dr. Vijayan served as Head of Technology Transfer at Rush University Medical Center.
During his more than a decade long career in technology transfer, he has co-founded a medical device company, served as consultant and advisor to biotech and pharma companies, served on various committees of Association of University Technology Managers (AUTM), Licensing Executive Society (LES), American Heart Association (AHA), Advanced Medical Technology Association (AdvaMed), Biotechnology Innovation Organization (BIO) and as a Scientist/Technology transfer reviewer on peer review panels of the Department of Defense (DOD) translational and clinical trial grants.
Dr. Vijayan received his PhD in Neuroscience and Physiology from the City University of New York and completed his thesis work in the laboratory of eminent Alzheimer Disease Scientist Prof. Khalid Iqbal. Subsequently, he trained as a post-doctoral fellow at the University of Chicago and the Jackson Laboratory, Bar Harbor. He received his MBA in Entrepreneurship from the University of Illinois.

FHL-101

FHL-101 is a small molecule derived from natural ingredients that promotes dopaminergic activity by maintaining sustained levels of proteins and neurotransmitters necessary for protection of dopaminergic neurons.

FHL-801

FHL-801 is a neutralizing antibody which protects dopaminergic neurons and reduces inflammation by inhibiting RANTES and eotaxin.

FHL-501

FHL-501 is a novel peptide which inhibits the NK-FB pathway to reduce inflammation and protect dopaminergic neurons.

Secret Plus+
High-Intensity Focused Ultrasound Hifu System

– Secret Plus+ High Indensity Focused Ultrasound System gives Face V-Lifting(Deep into your skin) while Xspurt HA Filler give volumization contouring . Amazing Effect!

Nuvogen Orchestra
Skin Boost Serum

– Combined Nuvogen Orchestra with Puraxel AESTHETIC ER: YAG LASER provides skin rejuvenation treatment, result in younger looking and better skin. Effects go to the epidermis layer in a non-invasive way, no pain. What the Magic!

Nuvogen Duet
Filling Serum

– Combined Nuvogen Duet with DermaShine Pro gives more volumization and provides skin regeneration treament. Both Filling Serum and Digital Micro-Needle Injector are in medical grade. Keep Safe!

Dermashine Pro
Digital Micro-Needle Injector

– Combined DermaShine Pro with Nuvogen Duet gives more volumization and provides skin regeneration treament. Both Filling Serum and Digital Micro-Needle Injector are in medical grade. Keep Safe!

Quotation Form

FHL-301

FHL-301 is a repurposed drug, a synthetic agonist of PPAR-Alpha helps in reducing inflammation and glial activation.

FHL-201

FHL-201 is another small molecule derived from natural ingredients and basically an endogenous ligand of PPAR-Alpha works by restoring striatal neuro transmitters and motor functions.

FHL-701

FHL-701 is a monoclonal antibody which inhibits an IL-12 subtype and has been shown to reduce the amyloid plaque load in the hippocampus, a significant marker for Alzheimer’s Disease.

FHL-601

FHL-601 is a repurposed drug which prevents damage of dopaminergic neurons by blocking CCR5 receptor and preventing T-cell infiltration, endorsed by anti-inflammatory mechanism of action.

FHL-401

FHL-401 isa novel peptide which protects the dopaminergic neurons by blocking the spread of synuclein associated pathology and inflammation by interfering with TLR-2- MyD88 signals.